Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Left ventricular hypertrophy: diagnostics pitfalls.

Robert Francis Bonvini1, Edoardo Camenzind

  • 1Cardiology Division of University Hospital of Geneva, Switzerland.

Swiss Medical Weekly
|July 10, 2004
PubMed
Summary

Distinguishing hypertrophic cardiomyopathy (HCM) from cardiac amyloidosis can be difficult. Endomyocardial biopsy (EMB) is crucial for diagnosing cardiac amyloidosis, especially in cases of multiorgan failure, guiding definitive treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Influence of the Residual Gensini Score on Prognosis of Patients With ST-Elevation Myocardial Infarction.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026
Same author

Coronary Ectasia and ST Elevation Myocardial Infarction Patients: Does Atherosclerosis Influence Periprocedural Management and Long-Term Prognosis?

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Feasibility and Safety of Transfemoral Aortic Valve Replacement Using Local Anesthesia in the Catheterization Suite Versus General Anesthesia in the Operation Theater.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2025
Same author

Diagnostic accuracy of low-dose myocardial perfusion imaging in a real-world setting.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2025
Same author

Coronary Embolism Among Patients With ST-Segment-Elevation Myocardial Infarction and Atrial Fibrillation: An Underrecognized But Deadly Association.

Journal of the American Heart Association·2024
Same author

Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2023

Area of Science:

  • Cardiology
  • Cardiovascular Diseases
  • Cardiac Imaging

Background:

  • Isolated left ventricular hypertrophy (LVH) is often presumed to be hypertrophic cardiomyopathy (HCM).
  • However, other conditions, such as cardiac amyloidosis, can mimic HCM, presenting diagnostic challenges.
  • Accurate differentiation is critical due to distinct prognoses and therapeutic strategies.

Purpose of the Study:

  • To highlight the diagnostic challenges in differentiating cardiac amyloidosis from hypertrophic cardiomyopathy (HCM) when isolated left ventricular hypertrophy is present.
  • To emphasize the limitations of non-invasive cardiac investigations in distinguishing between these two conditions.
  • To underscore the definitive role of endomyocardial biopsy (EMB) in diagnosing cardiac amyloidosis.

Main Methods:

  • Review of a clinical case presenting with isolated left ventricular hypertrophy.
  • Evaluation of non-invasive cardiac investigations (e.g., echocardiography, cardiac MRI).
  • Consideration of endomyocardial biopsy (EMB) for definitive diagnosis.

Main Results:

  • Non-invasive cardiac investigations were inconclusive in differentiating between hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis.
  • Endomyocardial biopsy (EMB) confirmed cardiac involvement secondary to systemic amyloidosis.
  • The case involved multiorgan failure, complicating the diagnostic and therapeutic pathway.

Conclusions:

  • Cardiac amyloidosis poses a significant diagnostic challenge, often mimicking hypertrophic cardiomyopathy (HCM).
  • Endomyocardial biopsy (EMB) remains the gold standard for confirming cardiac amyloidosis.
  • A multidisciplinary approach is essential for accurate diagnosis and tailored treatment planning in complex cardiac cases.

Related Experiment Videos